Ionis Pharmaceuticals - IONS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $47.80
  • Forecasted Upside: 11.92%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.23 (0.54%)

This chart shows the closing price for IONS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ionis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IONS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IONS

Analyst Price Target is $47.80
▲ +11.92% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $47.80, with a high forecast of $67.00 and a low forecast of $27.00. The average price target represents a 11.92% upside from the last price of $42.71.

This chart shows the closing price for IONS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Ionis Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00N/A
7/31/2023CitigroupUpgradeNeutral ➝ Buy$36.00 ➝ $60.00Low
5/4/2023VNET GroupReiterated RatingMaintainsLow
5/4/2023CitigroupUpgradeSell ➝ Neutral$30.00 ➝ $36.00Low
5/4/2023BarclaysLower Target$40.00 ➝ $37.00Low
4/11/2023Morgan StanleyBoost TargetEqual Weight$40.00 ➝ $42.00Low
3/21/2023Sanford C. BernsteinInitiated CoverageUnderperform$31.00Low
2/23/2023SVB LeerinkLower TargetMarket Perform$34.00 ➝ $27.00Low
2/23/2023Royal Bank of CanadaReiterated RatingOutperform$65.00Low
2/23/2023SVB SecuritiesLower Target$34.00 ➝ $27.00Low
2/23/2023Needham & Company LLCReiterated RatingBuy$60.00Low
2/23/2023BMO Capital MarketsLower TargetOutperform$70.00 ➝ $67.00Low
2/23/2023BarclaysLower TargetEqual Weight$44.00 ➝ $40.00Low
2/3/2023SVB LeerinkBoost TargetMarket Perform$33.00 ➝ $34.00Low
1/23/2023SVB LeerinkBoost TargetMarket Perform$32.00 ➝ $33.00Low
1/19/2023Piper SandlerBoost TargetOverweight$60.00 ➝ $62.00Low
12/21/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$56.00 ➝ $40.00Low
11/15/2022BarclaysBoost Target$44.00Low
11/10/2022Morgan StanleyLower TargetOverweight$57.00 ➝ $56.00Low
11/10/2022SVB LeerinkLower TargetMarket Perform$30.00 ➝ $26.00Low
11/10/2022CitigroupBoost TargetSell$28.00 ➝ $31.00Low
11/9/2022Piper SandlerBoost Target$58.00 ➝ $60.00Low
9/9/2022Morgan StanleyUpgradeUnderweight ➝ Overweight$30.00 ➝ $57.00Low
8/10/2022CitigroupBoost TargetSell$26.00 ➝ $28.00Low
7/26/2022Piper SandlerBoost TargetOverweight$55.00 ➝ $58.00Low
7/18/2022OppenheimerReiterated RatingOutperform$59.00Low
6/21/2022SVB LeerinkBoost TargetMarket Perform$26.00 ➝ $27.00Low
6/10/2022Piper SandlerBoost Target$54.00 ➝ $55.00High
5/5/2022Stifel NicolausBoost Target$31.00 ➝ $33.00Low
4/1/2022SVB LeerinkLower TargetMarket Perform$29.00 ➝ $26.00High
3/1/2022GuggenheimInitiated CoverageBuy$64.00Medium
2/28/2022CitigroupInitiated CoverageSell$26.00Medium
2/25/2022SVB LeerinkLower TargetMarket Perform$34.00 ➝ $29.00Medium
2/1/2022Bank of AmericaDowngradeBuy ➝ Underperform$40.00 ➝ $30.00High
12/17/2021SVB LeerinkLower TargetMarket Perform$36.00 ➝ $34.00High
12/14/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
12/10/2021BMO Capital MarketsInitiated CoverageBuy$65.00Medium
12/8/2021SVB LeerinkLower TargetMarket Perform$39.00 ➝ $36.00High
11/4/2021Needham & Company LLCLower TargetBuy$84.00 ➝ $60.00Medium
11/4/2021SVB LeerinkBoost TargetMarket Perform$38.00 ➝ $39.00Medium
10/12/2021Morgan StanleyLower TargetUnderweight$33.00 ➝ $31.00Low
8/19/2021BMO Capital MarketsLower TargetOutperform$70.00 ➝ $68.00Low
8/5/2021SVB LeerinkLower TargetMarket Perform$41.00 ➝ $38.00High
7/16/2021Morgan StanleyLower TargetUnderweight$35.00 ➝ $33.00Medium
5/14/2021SVB LeerinkBoost TargetMarket Perform$36.00 ➝ $41.00Medium
5/7/2021UBS GroupUpgradeSell ➝ Neutral$33.00 ➝ $37.50High
5/6/2021Morgan StanleyLower TargetUnderweight$38.00 ➝ $35.00High
4/19/2021Morgan StanleyLower TargetUnderweight$43.00 ➝ $38.00Low
4/5/2021UBS GroupReiterated RatingReduceHigh
3/23/2021BMO Capital MarketsLower TargetPositive ➝ Outperform$90.00 ➝ $76.00High
3/23/2021Needham & Company LLCLower TargetBuy$95.00 ➝ $86.00High
3/23/2021SVB LeerinkLower TargetMarket Perform$50.00 ➝ $36.00High
3/23/2021Morgan StanleyLower TargetUnderweight$50.00 ➝ $43.00High
3/23/2021BarclaysLower TargetEqual Weight$52.00 ➝ $47.00High
3/23/2021Royal Bank of CanadaLower TargetPositive ➝ Outperform$76.00 ➝ $65.00High
3/22/2021Piper SandlerLower TargetNeutral$55.00 ➝ $45.00High
3/16/2021UBS GroupReiterated RatingSell$33.00Medium
3/1/2021BarclaysUpgradeUnderweight ➝ Equal Weight$50.00 ➝ $52.00Low
2/25/2021Morgan StanleyBoost TargetUnderweight$49.00 ➝ $50.00High
2/24/2021Piper SandlerLower TargetNeutral$60.00 ➝ $55.00High
12/15/2020UBS GroupInitiated CoverageSell$34.00Medium
12/15/2020CowenUpgradeMarket Perform ➝ OutperformHigh
11/5/2020Morgan StanleyLower TargetUnderweight$50.00 ➝ $49.00High
11/5/2020SVB LeerinkLower TargetMarket Perform$56.00 ➝ $50.00High
10/13/2020Morgan StanleyLower TargetUnderweight$54.00 ➝ $50.00Low
10/7/2020OppenheimerReiterated RatingBuy$69.00Low
9/22/2020OppenheimerInitiated CoverageBuy$69.00High
9/22/2020Cantor FitzgeraldBoost TargetNeutral$56.00 ➝ $59.00High
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
9/8/2020CitigroupLower Target$74.00 ➝ $78.00Low
9/2/2020BenchmarkInitiated CoverageHoldMedium
9/1/2020Royal Bank of CanadaBoost Target$71.00 ➝ $73.00Low
9/1/2020SVB LeerinkBoost TargetMarket Perform$54.00 ➝ $56.00Medium
9/1/2020OppenheimerLower TargetOutperform$74.00 ➝ $69.00Medium
9/1/2020Needham & Company LLCBoost TargetBuy$89.00 ➝ $91.00Medium
8/30/2020OppenheimerInitiated CoverageBuy$74.00High
8/10/2020CitigroupLower TargetBuy$80.00 ➝ $78.00High
8/6/2020Morgan StanleyLower TargetUnderweight$56.00 ➝ $54.00Low
8/6/2020OppenheimerReiterated RatingBuyLow
8/5/2020Needham & Company LLCInitiated CoverageBuy$89.00Low
8/5/2020William BlairReiterated RatingHoldLow
7/15/2020Morgan StanleyBoost TargetUnderweight$51.00 ➝ $56.00Low
7/15/2020Needham & Company LLCReiterated RatingBuy$89.00Medium
6/10/2020William BlairReiterated RatingHoldHigh
6/5/2020CitigroupBoost TargetBuy$71.00 ➝ $80.00High
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$71.00Medium
5/7/2020Morgan StanleyBoost TargetUnderweight$48.00 ➝ $51.00High
5/7/2020OppenheimerLower TargetOutperform$77.00 ➝ $74.00High
5/6/2020Needham & Company LLCReiterated RatingBuy$89.00High
4/9/2020CitigroupLower TargetBuy$73.00 ➝ $71.00Low
3/26/2020Cantor FitzgeraldLower TargetNeutral$65.00 ➝ $56.00High
3/9/2020JPMorgan Chase & Co.Boost TargetNeutral$58.00 ➝ $60.00Low
3/5/2020CitigroupInitiated CoverageBuy$73.00High
2/27/2020Piper SandlerLower TargetNeutral$70.00 ➝ $65.00High
1/30/2020BMO Capital MarketsReiterated RatingBuy$86.00High
1/24/2020William BlairReiterated RatingHoldLow
12/31/2019Bank of AmericaReiterated RatingBuy$70.00Medium
12/23/2019Needham & Company LLCReiterated RatingBuy$87.00Low
12/13/2019Needham & Company LLCReiterated RatingBuy$87.00Medium
12/12/2019OppenheimerInitiated CoverageBuy$77.00Low
11/14/2019William BlairInitiated CoverageMarket PerformLow
11/13/2019Bank of AmericaInitiated CoverageBuy$70.00Medium
11/7/2019Piper Jaffray CompaniesLower TargetNeutral$75.00 ➝ $70.00Medium
11/7/2019Needham & Company LLCReiterated RatingBuy$87.00Low
11/7/2019Morgan StanleyDowngradeEqual ➝ Equal Weight$63.00 ➝ $48.00Low
11/7/2019CowenReiterated RatingHoldLow
10/16/2019CowenReiterated RatingHoldHigh
10/15/2019Cantor FitzgeraldSet TargetHold$65.00N/A
10/11/2019Morgan StanleyLower TargetEqual Weight$68.00 ➝ $63.00Medium
10/10/2019Wells Fargo & CompanyBoost TargetOutperform$90.00 ➝ $120.00Medium
10/9/2019Needham & Company LLCSet TargetBuy$87.00Low
9/23/2019Wells Fargo & CompanyReiterated RatingBuyMedium
9/10/2019Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$80.00High
8/7/2019Evercore ISISet TargetHold$76.00Low
7/24/2019BMO Capital MarketsLower TargetOutperform$96.00 ➝ $95.00Low
5/24/2019Piper Jaffray CompaniesSet TargetHold$75.00Medium
4/24/2019Cantor FitzgeraldReiterated RatingHold$68.00Low
4/22/2019BMO Capital MarketsBoost TargetOutperform$96.00Low
4/18/2019Cantor FitzgeraldReiterated RatingHoldLow
4/9/2019Cantor FitzgeraldInitiated CoverageNeutral$68.00Medium
3/22/2019Piper Jaffray CompaniesSet TargetNeutral$63.00 ➝ $75.00Low
3/18/2019JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$47.00 ➝ $55.00Low
3/1/2019Morgan StanleySet TargetHold$71.00Low
3/1/2019Piper Jaffray CompaniesSet TargetHold$63.00Low
2/28/2019Piper Jaffray CompaniesBoost TargetNeutral$60.00Low
2/28/2019BMO Capital MarketsBoost TargetOutperform ➝ Outperform$70.00 ➝ $82.00Low
11/27/2018SVB LeerinkInitiated CoverageMarket Perform$50.00High
11/7/2018Morgan StanleySet TargetHold$46.00Low
11/6/2018Piper Jaffray CompaniesSet TargetHold$50.00Medium
10/3/2018Morgan StanleySet TargetHold$45.00Low
9/25/2018Stifel NicolausBoost TargetHold ➝ Hold$45.00 ➝ $48.00High
9/24/2018Piper Jaffray CompaniesSet TargetHold$50.00Medium
(Data available from 9/23/2018 forward)

News Sentiment Rating

1.13 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 13 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 13 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 11 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Ionis Pharmaceuticals logo
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
Read More

Today's Range

Now: $42.71
Low: $42.10
High: $43.07

50 Day Range

MA: $40.67
Low: $38.50
High: $43.64

52 Week Range

Now: $42.71
Low: $32.69
High: $47.74


704,520 shs

Average Volume

773,727 shs

Market Capitalization

$6.12 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?

The following equities research analysts have issued research reports on Ionis Pharmaceuticals in the last year: Barclays PLC, BMO Capital Markets, Citigroup Inc., Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein,, SVB Leerink LLC, SVB Securities, and VNET Group, Inc..
View the latest analyst ratings for IONS.

What is the current price target for Ionis Pharmaceuticals?

10 Wall Street analysts have set twelve-month price targets for Ionis Pharmaceuticals in the last year. Their average twelve-month price target is $47.80, suggesting a possible upside of 11.9%. BMO Capital Markets has the highest price target set, predicting IONS will reach $67.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $27.00 for Ionis Pharmaceuticals in the next year.
View the latest price targets for IONS.

What is the current consensus analyst rating for Ionis Pharmaceuticals?

Ionis Pharmaceuticals currently has 1 sell rating, 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IONS, but not buy more shares or sell existing shares.
View the latest ratings for IONS.

What other companies compete with Ionis Pharmaceuticals?

How do I contact Ionis Pharmaceuticals' investor relations team?

Ionis Pharmaceuticals' physical mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company's listed phone number is (760) 931-9200 and its investor relations email address is The official website for Ionis Pharmaceuticals is Learn More about contacing Ionis Pharmaceuticals investor relations.